Todd Pitts
Concepts (400)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 24 | 2024 | 792 | 2.750 |
Why?
| | Xenograft Model Antitumor Assays | 38 | 2024 | 870 | 1.920 |
Why?
| | Protein Kinase Inhibitors | 19 | 2020 | 907 | 1.800 |
Why?
| | Triple Negative Breast Neoplasms | 7 | 2024 | 203 | 1.390 |
Why?
| | Antineoplastic Agents | 25 | 2020 | 2152 | 1.380 |
Why?
| | Azepines | 5 | 2024 | 97 | 1.340 |
Why?
| | Histone Deacetylase Inhibitors | 5 | 2024 | 209 | 1.200 |
Why?
| | Cell Line, Tumor | 38 | 2025 | 3397 | 1.140 |
Why?
| | Pyrimidines | 9 | 2020 | 472 | 1.130 |
Why?
| | Mice, Nude | 25 | 2024 | 688 | 1.110 |
Why?
| | Pyrazines | 6 | 2018 | 86 | 0.990 |
Why?
| | Pancreatic Neoplasms | 7 | 2025 | 859 | 0.980 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2025 | 267 | 0.980 |
Why?
| | Cell Proliferation | 22 | 2024 | 2480 | 0.920 |
Why?
| | Apoptosis | 22 | 2024 | 2551 | 0.750 |
Why?
| | Fluorouracil | 1 | 2022 | 204 | 0.720 |
Why?
| | Proto-Oncogene Proteins | 6 | 2018 | 621 | 0.620 |
Why?
| | Benzimidazoles | 6 | 2024 | 177 | 0.610 |
Why?
| | Aurora Kinase A | 4 | 2020 | 55 | 0.610 |
Why?
| | Camptothecin | 5 | 2022 | 122 | 0.600 |
Why?
| | Imidazoles | 4 | 2018 | 239 | 0.600 |
Why?
| | Drug Resistance, Neoplasm | 12 | 2024 | 801 | 0.560 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1742 | 0.530 |
Why?
| | Drug Synergism | 4 | 2014 | 367 | 0.530 |
Why?
| | Mice | 42 | 2025 | 17828 | 0.520 |
Why?
| | Neoplasms | 9 | 2022 | 2687 | 0.480 |
Why?
| | Cell Cycle Proteins | 2 | 2018 | 617 | 0.480 |
Why?
| | Cell Cycle Checkpoints | 3 | 2019 | 97 | 0.470 |
Why?
| | Hydroxamic Acids | 3 | 2011 | 90 | 0.470 |
Why?
| | Wnt Signaling Pathway | 5 | 2024 | 197 | 0.460 |
Why?
| | Deoxycytidine | 3 | 2024 | 192 | 0.450 |
Why?
| | Melanoma | 5 | 2024 | 757 | 0.450 |
Why?
| | Receptor, IGF Type 1 | 3 | 2013 | 64 | 0.450 |
Why?
| | Animals | 47 | 2025 | 37243 | 0.440 |
Why?
| | Disease Models, Animal | 11 | 2025 | 4316 | 0.440 |
Why?
| | Pyrazoles | 5 | 2018 | 425 | 0.430 |
Why?
| | Gene Expression Regulation, Neoplastic | 10 | 2024 | 1395 | 0.430 |
Why?
| | Adrenocortical Carcinoma | 3 | 2020 | 63 | 0.430 |
Why?
| | Antimitotic Agents | 1 | 2013 | 8 | 0.420 |
Why?
| | Tumor Microenvironment | 5 | 2022 | 668 | 0.420 |
Why?
| | Mitogen-Activated Protein Kinases | 3 | 2014 | 316 | 0.420 |
Why?
| | Tumor Suppressor Protein p53 | 5 | 2024 | 527 | 0.410 |
Why?
| | Molecular Targeted Therapy | 3 | 2024 | 413 | 0.410 |
Why?
| | Signal Transduction | 18 | 2024 | 5092 | 0.400 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 4 | 2022 | 44 | 0.400 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2013 | 131 | 0.390 |
Why?
| | Boronic Acids | 2 | 2011 | 35 | 0.380 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2018 | 416 | 0.380 |
Why?
| | Quinoxalines | 4 | 2020 | 67 | 0.360 |
Why?
| | Dasatinib | 2 | 2024 | 56 | 0.350 |
Why?
| | Gene Expression Profiling | 8 | 2024 | 1746 | 0.340 |
Why?
| | Colonic Neoplasms | 2 | 2013 | 247 | 0.340 |
Why?
| | Drug Screening Assays, Antitumor | 5 | 2020 | 193 | 0.330 |
Why?
| | Humans | 68 | 2025 | 138972 | 0.330 |
Why?
| | Biomarkers, Tumor | 6 | 2018 | 1229 | 0.320 |
Why?
| | Heterografts | 3 | 2021 | 135 | 0.320 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2025 | 254 | 0.310 |
Why?
| | Oxidoreductases Acting on CH-CH Group Donors | 2 | 2020 | 27 | 0.310 |
Why?
| | Phosphatidylinositol 3-Kinases | 6 | 2018 | 368 | 0.290 |
Why?
| | Adrenal Cortex Neoplasms | 2 | 2020 | 60 | 0.280 |
Why?
| | Ephrin-B2 | 2 | 2019 | 45 | 0.280 |
Why?
| | Cell Cycle | 7 | 2018 | 593 | 0.270 |
Why?
| | Enzyme Inhibitors | 5 | 2020 | 850 | 0.270 |
Why?
| | Piperazines | 2 | 2020 | 345 | 0.270 |
Why?
| | Quinazolines | 3 | 2015 | 249 | 0.260 |
Why?
| | Drug Delivery Systems | 1 | 2010 | 359 | 0.260 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2024 | 814 | 0.250 |
Why?
| | Anilides | 2 | 2018 | 70 | 0.250 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2018 | 206 | 0.250 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 3 | 2019 | 132 | 0.240 |
Why?
| | Female | 41 | 2025 | 74016 | 0.240 |
Why?
| | Protein-Lysine 6-Oxidase | 1 | 2025 | 15 | 0.240 |
Why?
| | Gene Dosage | 4 | 2015 | 141 | 0.230 |
Why?
| | Organoids | 2 | 2024 | 119 | 0.230 |
Why?
| | Mutation | 9 | 2018 | 3984 | 0.230 |
Why?
| | Nephritis, Interstitial | 1 | 2025 | 12 | 0.230 |
Why?
| | Immunoblotting | 6 | 2015 | 309 | 0.230 |
Why?
| | Cyclosporine | 2 | 2018 | 266 | 0.220 |
Why?
| | Gene Regulatory Networks | 2 | 2024 | 310 | 0.220 |
Why?
| | Collagen Type I | 1 | 2025 | 139 | 0.220 |
Why?
| | Pyrimidinones | 2 | 2015 | 114 | 0.220 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2018 | 221 | 0.220 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2020 | 205 | 0.210 |
Why?
| | RNA, Small Interfering | 2 | 2024 | 626 | 0.210 |
Why?
| | ras Proteins | 4 | 2013 | 148 | 0.210 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 6 | 2016 | 262 | 0.210 |
Why?
| | Endogenous Retroviruses | 1 | 2024 | 38 | 0.210 |
Why?
| | Bevacizumab | 1 | 2024 | 139 | 0.210 |
Why?
| | Receptor, Notch1 | 2 | 2015 | 65 | 0.210 |
Why?
| | Pyridones | 2 | 2015 | 170 | 0.200 |
Why?
| | Mucous Membrane | 1 | 2024 | 126 | 0.200 |
Why?
| | Neoplasm Transplantation | 4 | 2018 | 249 | 0.200 |
Why?
| | Pyridines | 2 | 2018 | 494 | 0.200 |
Why?
| | Paclitaxel | 1 | 2024 | 237 | 0.200 |
Why?
| | Collagen | 1 | 2025 | 459 | 0.200 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2020 | 190 | 0.190 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 65 | 0.190 |
Why?
| | HCT116 Cells | 3 | 2018 | 80 | 0.190 |
Why?
| | Immunotherapy | 3 | 2022 | 633 | 0.190 |
Why?
| | Doxorubicin | 1 | 2024 | 350 | 0.180 |
Why?
| | Drug Design | 2 | 2013 | 165 | 0.180 |
Why?
| | beta Catenin | 2 | 2020 | 253 | 0.180 |
Why?
| | Gene Knockdown Techniques | 4 | 2020 | 329 | 0.170 |
Why?
| | Momordica charantia | 1 | 2020 | 15 | 0.170 |
Why?
| | DNA-Binding Proteins | 2 | 2020 | 1473 | 0.160 |
Why?
| | Benzoxazoles | 1 | 2020 | 19 | 0.160 |
Why?
| | HT29 Cells | 2 | 2018 | 41 | 0.160 |
Why?
| | Neoplasms, Experimental | 2 | 2019 | 174 | 0.160 |
Why?
| | Immune System | 1 | 2021 | 181 | 0.160 |
Why?
| | eIF-2 Kinase | 1 | 2019 | 31 | 0.160 |
Why?
| | src-Family Kinases | 2 | 2017 | 93 | 0.150 |
Why?
| | Receptor, EphB4 | 1 | 2019 | 33 | 0.150 |
Why?
| | Inhibitory Concentration 50 | 2 | 2016 | 89 | 0.150 |
Why?
| | DNA Helicases | 1 | 2020 | 138 | 0.150 |
Why?
| | Tumor Burden | 2 | 2018 | 307 | 0.150 |
Why?
| | Breast Neoplasms, Male | 1 | 2018 | 29 | 0.140 |
Why?
| | Coenzymes | 1 | 2018 | 19 | 0.140 |
Why?
| | Plant Extracts | 1 | 2020 | 209 | 0.140 |
Why?
| | 4-Aminobenzoic Acid | 1 | 2018 | 8 | 0.140 |
Why?
| | Thermodynamics | 1 | 2020 | 423 | 0.140 |
Why?
| | MAP Kinase Kinase Kinases | 2 | 2015 | 72 | 0.140 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 433 | 0.140 |
Why?
| | Septins | 1 | 2018 | 43 | 0.140 |
Why?
| | Adrenal Cortex | 1 | 2018 | 33 | 0.140 |
Why?
| | Oncogene Proteins v-abl | 1 | 2017 | 5 | 0.140 |
Why?
| | Neoplasm Invasiveness | 3 | 2020 | 501 | 0.140 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 35 | 0.140 |
Why?
| | Angiogenesis Inhibitors | 3 | 2018 | 230 | 0.130 |
Why?
| | Kidney | 1 | 2025 | 1467 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2014 | 85 | 0.130 |
Why?
| | Skin Neoplasms | 1 | 2024 | 837 | 0.130 |
Why?
| | Ubiquitin-Activating Enzymes | 1 | 2016 | 17 | 0.130 |
Why?
| | Cyclopentanes | 1 | 2016 | 19 | 0.130 |
Why?
| | Transplantation, Heterologous | 4 | 2022 | 193 | 0.130 |
Why?
| | Tumor Cells, Cultured | 4 | 2020 | 956 | 0.130 |
Why?
| | Corynebacterium | 1 | 2017 | 49 | 0.120 |
Why?
| | Corynebacterium Infections | 1 | 2017 | 42 | 0.120 |
Why?
| | Tankyrases | 1 | 2016 | 13 | 0.120 |
Why?
| | Cetuximab | 1 | 2016 | 98 | 0.120 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2018 | 325 | 0.120 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 122 | 0.120 |
Why?
| | Capecitabine | 1 | 2015 | 41 | 0.120 |
Why?
| | Amyloid Precursor Protein Secretases | 2 | 2013 | 79 | 0.120 |
Why?
| | Biliary Tract Neoplasms | 1 | 2015 | 29 | 0.120 |
Why?
| | Autophagy | 1 | 2018 | 286 | 0.120 |
Why?
| | Drug Discovery | 1 | 2016 | 144 | 0.120 |
Why?
| | Genes, ras | 2 | 2018 | 94 | 0.120 |
Why?
| | Adenocarcinoma | 2 | 2020 | 882 | 0.120 |
Why?
| | Cell Survival | 3 | 2019 | 1126 | 0.110 |
Why?
| | Diphenylamine | 1 | 2014 | 9 | 0.110 |
Why?
| | Gene Expression Regulation | 1 | 2024 | 2591 | 0.110 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 179 | 0.110 |
Why?
| | Germ-Line Mutation | 2 | 2018 | 170 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2014 | 72 | 0.110 |
Why?
| | Piperidines | 1 | 2015 | 216 | 0.110 |
Why?
| | Middle Aged | 14 | 2024 | 33782 | 0.100 |
Why?
| | Protein Kinases | 1 | 2015 | 308 | 0.100 |
Why?
| | Benzamides | 1 | 2014 | 213 | 0.100 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2016 | 254 | 0.100 |
Why?
| | Up-Regulation | 1 | 2016 | 852 | 0.100 |
Why?
| | Receptor, Insulin | 1 | 2013 | 100 | 0.100 |
Why?
| | Tetrahydronaphthalenes | 1 | 2013 | 30 | 0.100 |
Why?
| | Valine | 1 | 2013 | 77 | 0.100 |
Why?
| | Aged | 11 | 2024 | 24172 | 0.100 |
Why?
| | Neutrophils | 4 | 2019 | 1274 | 0.100 |
Why?
| | Bortezomib | 2 | 2011 | 53 | 0.100 |
Why?
| | Receptors, Notch | 1 | 2013 | 87 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 1 | 2015 | 322 | 0.100 |
Why?
| | Mitosis | 1 | 2013 | 192 | 0.100 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2013 | 191 | 0.090 |
Why?
| | 3' Untranslated Regions | 1 | 2012 | 145 | 0.090 |
Why?
| | Head and Neck Neoplasms | 1 | 2016 | 549 | 0.090 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2012 | 100 | 0.090 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2016 | 637 | 0.090 |
Why?
| | Sirolimus | 1 | 2013 | 277 | 0.090 |
Why?
| | Proteasome Inhibitors | 1 | 2011 | 43 | 0.090 |
Why?
| | Computational Biology | 1 | 2015 | 650 | 0.090 |
Why?
| | Benzodioxoles | 1 | 2012 | 116 | 0.090 |
Why?
| | Protease Inhibitors | 1 | 2011 | 104 | 0.080 |
Why?
| | Carcinogenesis | 2 | 2024 | 215 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-akt | 4 | 2018 | 442 | 0.080 |
Why?
| | Mice, Inbred NOD | 2 | 2022 | 593 | 0.080 |
Why?
| | Nuclear Proteins | 1 | 2015 | 707 | 0.080 |
Why?
| | Phosphorylation | 4 | 2019 | 1767 | 0.080 |
Why?
| | Neoplasm Metastasis | 3 | 2018 | 667 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor Receptor-3 | 1 | 2009 | 7 | 0.080 |
Why?
| | Adult | 12 | 2024 | 38393 | 0.080 |
Why?
| | Mice, Inbred BALB C | 3 | 2020 | 1261 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2009 | 72 | 0.080 |
Why?
| | Breast Neoplasms | 2 | 2012 | 2283 | 0.070 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 3 | 2014 | 97 | 0.070 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2009 | 75 | 0.070 |
Why?
| | Cell Movement | 2 | 2011 | 969 | 0.070 |
Why?
| | Male | 15 | 2024 | 68250 | 0.070 |
Why?
| | Positron-Emission Tomography | 3 | 2018 | 304 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 848 | 0.070 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2011 | 339 | 0.070 |
Why?
| | Prognosis | 4 | 2019 | 3995 | 0.070 |
Why?
| | Farnesyltranstransferase | 1 | 2007 | 35 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2015 | 761 | 0.060 |
Why?
| | Protein Conformation | 2 | 2020 | 944 | 0.060 |
Why?
| | Gene Expression | 2 | 2019 | 1487 | 0.060 |
Why?
| | Microsatellite Repeats | 2 | 2024 | 160 | 0.060 |
Why?
| | Feasibility Studies | 1 | 2010 | 980 | 0.060 |
Why?
| | Maximum Tolerated Dose | 2 | 2020 | 204 | 0.060 |
Why?
| | Algorithms | 3 | 2024 | 1730 | 0.060 |
Why?
| | Transcription, Genetic | 2 | 2024 | 1471 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2010 | 3313 | 0.060 |
Why?
| | Quinolones | 1 | 2007 | 135 | 0.060 |
Why?
| | Ipilimumab | 1 | 2025 | 32 | 0.060 |
Why?
| | Neovascularization, Pathologic | 2 | 2018 | 296 | 0.060 |
Why?
| | Disease Progression | 2 | 2025 | 2752 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2025 | 99 | 0.050 |
Why?
| | Models, Molecular | 2 | 2020 | 1597 | 0.050 |
Why?
| | Structure-Activity Relationship | 2 | 2018 | 570 | 0.050 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2019 | 40 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 154 | 0.050 |
Why?
| | Enhancer Elements, Genetic | 1 | 2024 | 190 | 0.050 |
Why?
| | HMGB1 Protein | 1 | 2003 | 50 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 2002 | 44 | 0.050 |
Why?
| | Adrenergic alpha-Agonists | 1 | 2002 | 28 | 0.050 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2002 | 34 | 0.050 |
Why?
| | Neuroimmunomodulation | 1 | 2002 | 66 | 0.050 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2018 | 611 | 0.050 |
Why?
| | Histone Deacetylase 1 | 1 | 2022 | 20 | 0.050 |
Why?
| | Isoenzymes | 1 | 2003 | 304 | 0.050 |
Why?
| | Adrenergic beta-Agonists | 1 | 2002 | 97 | 0.050 |
Why?
| | Aurora Kinases | 2 | 2012 | 28 | 0.050 |
Why?
| | Histones | 2 | 2022 | 632 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2024 | 10921 | 0.050 |
Why?
| | Endotoxemia | 1 | 2002 | 87 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2010 | 2362 | 0.040 |
Why?
| | Caspase 3 | 2 | 2013 | 251 | 0.040 |
Why?
| | Acetylation | 1 | 2022 | 244 | 0.040 |
Why?
| | Chimerism | 1 | 2021 | 32 | 0.040 |
Why?
| | Extracellular Matrix | 1 | 2025 | 539 | 0.040 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2002 | 228 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2019 | 1192 | 0.040 |
Why?
| | Campylobacter jejuni | 1 | 2000 | 13 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 88 | 0.040 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 79 | 0.040 |
Why?
| | Cluster Analysis | 2 | 2012 | 517 | 0.040 |
Why?
| | Catalase | 1 | 2000 | 134 | 0.040 |
Why?
| | TCF Transcription Factors | 1 | 2020 | 17 | 0.040 |
Why?
| | Histone Deacetylases | 1 | 2022 | 209 | 0.040 |
Why?
| | RNA, Neoplasm | 1 | 2020 | 80 | 0.040 |
Why?
| | Mice, SCID | 1 | 2021 | 368 | 0.040 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2020 | 93 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 62 | 0.040 |
Why?
| | Indolizines | 1 | 2019 | 4 | 0.040 |
Why?
| | Forkhead Box Protein M1 | 1 | 2019 | 7 | 0.040 |
Why?
| | Small Molecule Libraries | 1 | 2020 | 94 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 129 | 0.040 |
Why?
| | MAP Kinase Kinase 2 | 2 | 2013 | 28 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 797 | 0.040 |
Why?
| | MAP Kinase Kinase 1 | 2 | 2013 | 75 | 0.040 |
Why?
| | Crystallography, X-Ray | 1 | 2020 | 480 | 0.040 |
Why?
| | Genetic Linkage | 1 | 1999 | 289 | 0.040 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2018 | 24 | 0.040 |
Why?
| | High-Throughput Screening Assays | 1 | 2020 | 157 | 0.040 |
Why?
| | Flavin-Adenine Dinucleotide | 1 | 2018 | 17 | 0.040 |
Why?
| | NADP | 1 | 2018 | 53 | 0.040 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2020 | 210 | 0.040 |
Why?
| | Multifactorial Inheritance | 1 | 1999 | 170 | 0.030 |
Why?
| | Nausea | 1 | 2018 | 111 | 0.030 |
Why?
| | Radiotherapy | 1 | 2019 | 207 | 0.030 |
Why?
| | Aldosterone | 1 | 2018 | 42 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 897 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1031 | 0.030 |
Why?
| | Area Under Curve | 1 | 2018 | 319 | 0.030 |
Why?
| | Breast | 1 | 2018 | 158 | 0.030 |
Why?
| | Hemorrhage | 1 | 2002 | 747 | 0.030 |
Why?
| | DNA Damage | 1 | 2020 | 422 | 0.030 |
Why?
| | Diarrhea | 1 | 2018 | 182 | 0.030 |
Why?
| | Catalytic Domain | 1 | 2018 | 227 | 0.030 |
Why?
| | RNA | 1 | 2024 | 925 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2020 | 1355 | 0.030 |
Why?
| | Autistic Disorder | 1 | 1999 | 206 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2018 | 704 | 0.030 |
Why?
| | Axin Protein | 1 | 2016 | 19 | 0.030 |
Why?
| | Ubiquitination | 1 | 2016 | 105 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 337 | 0.030 |
Why?
| | Hypertension | 2 | 2018 | 1249 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2019 | 386 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2020 | 2815 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2017 | 397 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 787 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 449 | 0.030 |
Why?
| | Serrate-Jagged Proteins | 1 | 2015 | 27 | 0.030 |
Why?
| | Jagged-1 Protein | 1 | 2015 | 23 | 0.030 |
Why?
| | Tumor Protein p73 | 1 | 2015 | 14 | 0.030 |
Why?
| | Gene Duplication | 1 | 2015 | 65 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 661 | 0.030 |
Why?
| | Binding Sites | 1 | 2018 | 1317 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1072 | 0.030 |
Why?
| | NF-kappa B | 3 | 2003 | 678 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1730 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2015 | 241 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 215 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 3029 | 0.030 |
Why?
| | Caspase 7 | 1 | 2013 | 22 | 0.030 |
Why?
| | Butadienes | 1 | 2013 | 37 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2015 | 385 | 0.030 |
Why?
| | Cell Growth Processes | 1 | 2013 | 53 | 0.030 |
Why?
| | Survival Analysis | 1 | 2016 | 1311 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2012 | 34 | 0.020 |
Why?
| | Everolimus | 1 | 2013 | 109 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2019 | 910 | 0.020 |
Why?
| | Nitriles | 1 | 2013 | 176 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3143 | 0.020 |
Why?
| | Random Allocation | 1 | 2013 | 362 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2012 | 155 | 0.020 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 2 | 2003 | 145 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2015 | 1370 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2003 | 280 | 0.020 |
Why?
| | Calcium Signaling | 1 | 2013 | 250 | 0.020 |
Why?
| | Kinetics | 1 | 2014 | 1649 | 0.020 |
Why?
| | Enzyme Activation | 2 | 2003 | 819 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2012 | 310 | 0.020 |
Why?
| | Cellular Senescence | 1 | 2012 | 190 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 163 | 0.020 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2010 | 14 | 0.020 |
Why?
| | Receptor, ErbB-2 | 1 | 2012 | 349 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2010 | 72 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2011 | 159 | 0.020 |
Why?
| | Population Groups | 1 | 2010 | 59 | 0.020 |
Why?
| | Neutropenia | 1 | 2010 | 157 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2010 | 111 | 0.020 |
Why?
| | Capillary Permeability | 1 | 2010 | 147 | 0.020 |
Why?
| | Ligands | 1 | 2011 | 666 | 0.020 |
Why?
| | Metabolome | 1 | 2013 | 352 | 0.020 |
Why?
| | Drug Combinations | 1 | 2010 | 346 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2011 | 342 | 0.020 |
Why?
| | Keratinocytes | 1 | 2010 | 252 | 0.020 |
Why?
| | Transcriptome | 1 | 2015 | 966 | 0.020 |
Why?
| | Australia | 1 | 2010 | 307 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2015 | 1149 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2015 | 1437 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 4095 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 984 | 0.020 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2007 | 14 | 0.020 |
Why?
| | Sulfonamides | 1 | 2011 | 505 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 850 | 0.020 |
Why?
| | Calcium | 1 | 2013 | 1188 | 0.020 |
Why?
| | Verapamil | 1 | 2007 | 40 | 0.020 |
Why?
| | Blotting, Western | 1 | 2009 | 1232 | 0.020 |
Why?
| | Clone Cells | 1 | 2007 | 265 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 2047 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3636 | 0.020 |
Why?
| | Calcium Channel Blockers | 1 | 2007 | 172 | 0.020 |
Why?
| | Family | 1 | 2010 | 680 | 0.010 |
Why?
| | MicroRNAs | 1 | 2012 | 676 | 0.010 |
Why?
| | Metabolomics | 1 | 2011 | 689 | 0.010 |
Why?
| | Cohort Studies | 1 | 2015 | 5744 | 0.010 |
Why?
| | Liver Neoplasms | 1 | 2011 | 719 | 0.010 |
Why?
| | Ovarian Neoplasms | 1 | 2010 | 573 | 0.010 |
Why?
| | Phosphotransferases | 1 | 2003 | 24 | 0.010 |
Why?
| | Class Ib Phosphatidylinositol 3-Kinase | 1 | 2003 | 3 | 0.010 |
Why?
| | bcl-Associated Death Protein | 1 | 2003 | 9 | 0.010 |
Why?
| | Phentolamine | 1 | 2002 | 18 | 0.010 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2002 | 25 | 0.010 |
Why?
| | Brimonidine Tartrate | 1 | 2002 | 10 | 0.010 |
Why?
| | Propranolol | 1 | 2002 | 45 | 0.010 |
Why?
| | Phenylephrine | 1 | 2002 | 75 | 0.010 |
Why?
| | Mice, Mutant Strains | 1 | 2003 | 309 | 0.010 |
Why?
| | Adolescent | 2 | 2018 | 21581 | 0.010 |
Why?
| | Chemokines | 1 | 2003 | 226 | 0.010 |
Why?
| | Peroxidase | 1 | 2002 | 182 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2002 | 150 | 0.010 |
Why?
| | Biological Transport | 1 | 2003 | 403 | 0.010 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2002 | 129 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 236 | 0.010 |
Why?
| | Young Adult | 1 | 2018 | 13371 | 0.010 |
Why?
| | Respiratory Burst | 1 | 2000 | 19 | 0.010 |
Why?
| | omega-N-Methylarginine | 1 | 2000 | 31 | 0.010 |
Why?
| | MAP Kinase Signaling System | 1 | 2002 | 322 | 0.010 |
Why?
| | Inflammation Mediators | 1 | 2003 | 513 | 0.010 |
Why?
| | Protein Processing, Post-Translational | 1 | 2002 | 462 | 0.010 |
Why?
| | Statistical Distributions | 1 | 1999 | 8 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2000 | 533 | 0.010 |
Why?
| | Matched-Pair Analysis | 1 | 1999 | 38 | 0.010 |
Why?
| | Intelligence Tests | 1 | 1999 | 61 | 0.010 |
Why?
| | Chromosomes, Human | 1 | 1999 | 44 | 0.010 |
Why?
| | Nuclear Family | 1 | 1999 | 57 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 2003 | 888 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2002 | 431 | 0.010 |
Why?
| | Hydrogen Peroxide | 1 | 2000 | 332 | 0.010 |
Why?
| | Linkage Disequilibrium | 1 | 1999 | 258 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2003 | 737 | 0.010 |
Why?
| | Models, Genetic | 1 | 1999 | 591 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2003 | 4182 | 0.010 |
Why?
| | Cytokines | 1 | 2003 | 2083 | 0.010 |
Why?
| | Cell Line | 1 | 2000 | 2879 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1999 | 2925 | 0.010 |
Why?
| | Genotype | 1 | 1999 | 1849 | 0.010 |
Why?
| | Sex Factors | 1 | 1999 | 2050 | 0.010 |
Why?
| | Macrophages | 1 | 2000 | 1543 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2003 | 5801 | 0.010 |
Why?
| | Child, Preschool | 1 | 1999 | 11158 | 0.000 |
Why?
| | Child | 1 | 1999 | 21936 | 0.000 |
Why?
|
|
Pitts's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|